Ajay Gopal
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium · Associate Professor of Medicine, Department of Medicine, University of Washington, Seattle, Washington.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
5
NIH RePORTER
Trial papers
77
PubMed author-name match
Trials
Studies that name Ajay Gopal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06442475 · Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington · recruiting · Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT04257578 · Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaUniversity of Washington · active not recruiting · B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma · principal investigator
- Ph2NCT02489123 · Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaUniversity of Washington · terminated · Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma · principal investigator
- Ph1NCT02483000 · Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell MalignanciesFred Hutchinson Cancer Center · terminated · Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma · principal investigator
- Ph1/Ph2NCT02227199 · Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin LymphomaUniversity of Washington · completed · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT01921387 · Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid MalignanciesFred Hutchinson Cancer Center · completed · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma · principal investigator
- Ph1NCT01678443 · Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesFred Hutchinson Cancer Center · terminated · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma · principal investigator
- Ph2NCT01434472 · High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaFred Hutchinson Cancer Center · terminated · Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT01165112 · Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaUniversity of Washington · completed · Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma · principal investigator
- Ph2NCT01110135 · Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaUniversity of Washington · completed · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma · principal investigator
- Ph1NCT00860171 · Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaFred Hutchinson Cancer Center · terminated · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT00843050 · A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell LymphomaPiramal Enterprises Limited · terminated · Mantle Cell Lymphoma · principal investigator
- Ph1/Ph2NCT00288067 · Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaNational Cancer Institute (NCI) · terminated · Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma · principal investigator
- Ph2NCT00119392 · Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaFred Hutchinson Cancer Center · completed · B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma · principal investigator
- Ph1NCT00110071 · Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaFred Hutchinson Cancer Center · completed · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma · principal investigator
- Ph2NCT00073918 · Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaFred Hutchinson Cancer Center · completed · Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · principal investigator
- Ph2NCT00072514 · Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesFred Hutchinson Cancer Center · completed · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2026 · $401,411 awarded in 2026Grant number is on one of their registry trials
- Molecularly Targeted Therapy for LymphomaK24CA184039 · NCI · UNIVERSITY OF WASHINGTON · fiscal years 2014 to 2018 · $171,401 awarded in 2018Same name and institution; not confirmed by an ID
- Radioimmunotherapy for LymphomaP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2005 to 2015 · $269,552 awarded in 2015Grant number is on one of their registry trials
- Proapoptotic Therapy for B-cell Non Hodgkin's LymphomaR21CA119519 · NCI · UNIVERSITY OF WASHINGTON · fiscal years 2006 to 2007 · $272,362 awarded in 2007Grant number is on one of their registry trials
- OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMAK23CA085479 · NCI · UNIVERSITY OF WASHINGTON · fiscal years 2000 to 2005 · $65,389 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:38 UTC. The ranking covers the 200 most relevant of 77 PubMed records, and a shared surname and initials can bring in a namesake. All 77 on PubMed
- Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.J Clin Oncol · 20121,170 citationsRCR 30.4
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med · 2014894 citationsRCR 24.0
- 587 citationsRCR 11.0
- 391 citationsRCR 9.6
- 358 citationsRCR 14.1
- 251 citationsRCR 5.8
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.Clin Cancer Res · 2018206 citationsRCR 6.0
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Br J Haematol · 2009191 citationsRCR 4.0
- 175 citationsRCR 5.5
- 171 citationsRCR 3.9